Otsuka (OTCMKTS:OTSKY) Reaches New 12-Month High – Still a Buy?

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) shares hit a new 52-week high during trading on Wednesday . The company traded as high as $38.20 and last traded at $38.01, with a volume of 51121 shares traded. The stock had previously closed at $36.32.

Otsuka Price Performance

The company has a debt-to-equity ratio of 0.05, a current ratio of 2.17 and a quick ratio of 1.67. The stock has a market capitalization of $40.83 billion, a price-to-earnings ratio of 15.27, a price-to-earnings-growth ratio of 8.02 and a beta of -0.04. The company has a 50-day simple moving average of $34.18 and a two-hundred day simple moving average of $33.67.

Otsuka (OTCMKTS:OTSKY) last announced its quarterly earnings results on Friday, July 31st. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.19. The company had revenue of $4.41 billion during the quarter, compared to the consensus estimate of $3.95 billion. Otsuka had a net margin of 15.50% and a return on equity of 12.93%. Otsuka has set its FY 2026 guidance at 2.119-2.119 EPS. On average, equities research analysts predict that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.96 earnings per share for the current year.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.